Trichomoniasis & Under-Recognized Male STIs
Trichomonas vaginalis, Ureaplasma, and the Overlooked Causes of Male Urethritis
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Metronidazole/tinidazole FDA-approved for trichomoniasis
Reference only. Not medical advice.
What can go wrong
Trichomoniasis is associated with increased risk of HIV acquisition and transmission and, in pregnancy, with adverse outcomes, making partner treatment important even when male symptoms are minimal. Metronidazole carries a disulfiram-like interaction with alcohol (advised to avoid alcohol during and shortly after treatment) and rare neurologic effects with prolonged use. Over-diagnosing and over-treating organisms of uncertain pathogenicity (Ureaplasma) contributes to antibiotic overuse. Persistent urethritis after appropriate treatment warrants re-evaluation rather than repeated empiric courses.
This is something to take to a clinician. The Atlas can tell you what is known about trichomoniasis & under-recognized male stis in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Trichomonas vaginalis, a flagellated protozoan, causes the most common curable non-viral STI globally, yet it is frequently overlooked in men because male infection is usually asymptomatic or causes only mild urethritis. The CDC's 2021 guidelines updated treatment for women to a 7-day metronidazole course (more effective than single-dose in trials), while single-dose remains used in men; partner treatment is essential to prevent ping-pong reinfection. This entry also covers other under-recognized contributors to male urethritis and genitourinary symptoms, including Ureaplasma urealyticum (whose pathogenic role is debated), adenovirus, and the often non-infectious or organism-negative cases of non-gonococcal urethritis that frustrate both patients and clinicians.
The most common curable non-viral STI worldwide is mostly silent in men, and routinely left off the panel.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
Trichomonas vaginalis adheres to urogenital epithelium and causes a localized inflammatory response; in men it tends to colonize the urethra transiently and often clears, which is part of why male symptoms are mild and underdiagnosed. Nitroimidazoles (metronidazole, tinidazole) are reduced intracellularly to reactive species that damage protozoal DNA. Ureaplasma and Mycoplasma hominis are commensal-to-pathogenic organisms whose contribution to male urethritis is debated, and over-treating asymptomatic colonization is discouraged. Many non-gonococcal urethritis cases have no identified organism on testing.
The under-recognition problem
Because male trichomoniasis is usually mild and self-limited, men act as a transmission reservoir, reinfecting partners if not treated. Wet-mount microscopy, still used in some clinics, is poorly sensitive in men, so NAAT is the preferred diagnostic. Trichomoniasis disproportionately affects some populations and is associated with increased HIV acquisition. The broader lesson is diagnostic humility: a meaningful fraction of male urethritis is not chlamydia or gonorrhea, and chasing organisms of uncertain significance (like Ureaplasma) can lead to unnecessary antibiotics, while NAAT-detectable but panel-omitted organisms like trichomonas and M. genitalium get missed.
What people get wrong
Often saidTrichomoniasis is only a women's infection
ActuallyMen are commonly infected, usually without symptoms, and act as a reservoir that reinfects partners unless treated.
Often saidEvery case of urethritis has an identifiable bug to kill
ActuallyA meaningful share of non-gonococcal urethritis is organism-negative or due to commensals of uncertain significance; reflexive antibiotic escalation is not the answer.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- Organism
- Trichomonas vaginalis (protozoan)
- Male presentation
- Usually asymptomatic or mild urethritis
- Treatment
- Metronidazole or tinidazole (nitroimidazoles)
- Diagnosis
- NAAT (far more sensitive than wet mount in men)
- Often omitted from
- Standard male STI panels
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Trichomoniasis & Under-Recognized Male STIs. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Kissinger et al., Lancet Infect Dis (multidose metronidazole)2018
7-day metronidazole more effective than single dose for trichomoniasis in women, informing the 2021 guideline change
CDC STI Treatment Guidelines2021
Updated trichomoniasis regimens and emphasized NAAT over microscopy
Bachmann et al. (NGU etiology studies)2010s
Characterized the mixed and often organism-negative etiology of non-gonococcal urethritis